Time Schedule
Monday, April 09 19:30-20:30 Opening Ceremony | 20:30-21:00 Keynote Speaker | 21:00-21:30 Discussion | 22:00 Dinner | Tuesday, April 10 07:00-08:00 Breakfast / Registration | 1st Session: Acute Coronary Syndrome (ACS): 08:00-09:15 | 08:00-08:25 Acute Coronary Syndrome Management: Current Challenges and Emerging Solutions. | 08:25-08:50 Dug Eluting Stent: An Update on Clinical Data. | 08:50-09:05 Antiplatelet Strategies in Acute Coronary Syndrome: Expanding Choices. | 09:15-09:30 Discussion | 09:30-09:40 Break | 2nd Session: Evolution of Antithrombotic Therapy Use in Acute Coronary Syndrome: 09:40-10:45 | 9:40-10:05 Anticoagulant in ACS and Beyond. | 10:05-10:30 Newer Antiplatelet: Confronting the Limitations of Antiplatelet Therapy. | 10:30-10:55 Risk of Bleeding: Balancing Risk and Benefit. | 10:55-11:10 Discussion | 11:10-11:20 Break | 3rd Session: Heart Failure (HF): 11:20-12:15 | 11:20-11:45 Heart Failure: Current Medical Therapy. | 11:45-12:10 Heart Rate as a Therapeutic Target in Heart Failure Patients. | 12:10-12:35 Devices and Technology in the Management of Heart Failure. | 12:35-12:50 Discussion | 12:50-14:00 Prayer Time, Lunch Break, Exhibition | 4th Session: Hypertension: 14:00-16:00 | 14:00-14:25 Update on Hypertension Management. | 14:25-14:50 JNC 8 (VIII): What is new going to be in the guidelines? | 14:50-15:15 Strategies for the Management of Resistant Hypertension. | 15:15-15:30 Discussion, Prayer Time | 5th Session: Ambulatory care in Cardiology: 15:30-16:45 | 15:30-15:55 Medication safety concerns in the cardiovascular patient. | 15:55-16:20 Lipid management: Optimizing Therapies Old and New. | 16:20-16:45 Primary prevention of cardiovascular disease: Tools and Strategies. | 16:45-17:00 Discussion | Wednesday, April 11 07:00-08:00 Breakfast / Registration | 1st Session: Atrial fibrillation (Afib): 08:00-09:15 | 08:00-08:25 Contemporary approach in Atrial Fibrillation Management. | 08:25-08:50 Antithrombotic Therapy in Afib: Defining the future of Oral Anticoagulant Therapy. | 08:50-09:15 Combined Atrial Fibrillation and Heart Failure: Challenges in Pharmacotherapy Management. | 09:15-09:30 Discussion | 09:30-09:40 Break | 2nd Session: End stage Heart Failure and Heart Transplant: 09:30-10:45 | 09:40-10:05 ICU Management of End Stage Heart Failure and Mechanical Circulatory Support Therapy. | 10:05-10:30 Heart Transplant: indication, selection, pre and post op care. | 10:30-10:55 Long Term Management of Heart Transplant and the Pharmacist Role. | 10:55-11:10 Discussion | 11:10-11:20 Break | 3rd Session: Venous Thromboembolism (VTE) Challenge and Valvular Heart Disease (VHD) Management: 11:00-12:15 | 11:20-11:45 VTE: Acute and Chronic Management. | 11:45-12:10 Contemporary Management of VHD in Various Medical Settings. | 12:10-12:35 Transcatheter Aortic Valve Implantation (TAVI): Highlight on Procedural and Pharmacotherapy Management Implications. | 12:35-12:50 Discussion | 12:50-14:00 Prayer Time, Lunch Break, Exhibition | 4th Session: Personalized Medicine in Cardiology: 14:00-16:00 | 14:00-14:25 Antiplatelet resistant / un-responsiveness: Genomic Markers and Advanced Testing. | 14:25-14:50 Tailored antiplatelet therapy: Pharmacogenomics or Dynamic Applications? | 14:50-15:15 Women cardiology: Differences in Diagnosis and Management. | 15:15-15:30 Discussion, Prayer | 5th Session: Pulmonary Hypertension: 15:30-16:45 | 15:30-15:55 Diagnosis and Treatment of Pulmonary Hypertension. | 15:55-16:20 Pulmonary Hypertension in ICU Setting. | 16:20-16:45 Perspectives on Pharmacoeconomic Appropriateness of Pulmonary Hypertension Medications. | 16:45-17:00 Discussion | 17:00-17:30: Closing Ceremony
Slider

Upon completion of the symposium, attendees should be able to:

  • Identify novel therapeutic interventions in cardiovascular diseases and how they could serve in their managements. 
  • Describe how new clinical trials regulate and modify the pharmacotherapeutic management of cardiovascular diseases.
  • Be aware of the latest developments in the epidemiological aspects of cardiovascular diseases.
  • Understand the recent developments in the management of atrial and ventricular arrhythmias. 
  • Be aware of the latest developments in the management of dyslipidemia. 
  • Have a better perspective of the management of thromboembolic diseases. 
  • Appreciate the recent advances and challenges in anticoagulant and antiplatelet therapy.  Understand the latest development in cardiovascular personalized medicine. 
  • Understand heart failure with preserved ejection fraction. 
  • Be aware of new pharmacological agents and ventricular assist devices for heart failure. 
  • Be aware of the management issues surrounding the heart transplant pharmacotherapy. 
  • Understand the latest developments in the management of systemic hypertension and pulmonary hypertension. 
  • Understand newer approaches to the management of acute coronary syndrome / acute myocardial infarction.    
  • Identify mechanisms by which clinical pharmacists could signal and participate in cardiovascular diseases pharmacotherapy.  
  • Identify mechanisms and interventions by which pharmacists could be able to establish specialized cardiology clinics and take a lead in cardiovascular disease management. 

Sponsors